113 related articles for article (PubMed ID: 19145048)
1. [Novel anti-cancer compounds targeting the cell cycle].
Hirai H; Shimomura T; Komatani H; Kotani H
Nihon Yakurigaku Zasshi; 2009 Jan; 133(1):27-31. PubMed ID: 19145048
[No Abstract] [Full Text] [Related]
2. [The serine/threonine kinases that control cell cycle progression as therapeutic targets].
Diallo A; Prigent C
Bull Cancer; 2011 Nov; 98(11):1335-45. PubMed ID: 22020767
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic opportunities to control tumor cell cycles.
Malumbres M
Clin Transl Oncol; 2006 Jun; 8(6):399-408. PubMed ID: 16790392
[TBL] [Abstract][Full Text] [Related]
4. Cell cycle kinases as therapeutic targets for cancer.
Lapenna S; Giordano A
Nat Rev Drug Discov; 2009 Jul; 8(7):547-66. PubMed ID: 19568282
[TBL] [Abstract][Full Text] [Related]
5. Phenylacetate inhibits growth and modulates cell cycle gene expression in renal cancer cell lines.
Franco OE; Onishi T; Umeda Y; Soga N; Wakita T; Arima K; Yanagawa M; Sugimura Y
Anticancer Res; 2003; 23(2B):1637-42. PubMed ID: 12820434
[TBL] [Abstract][Full Text] [Related]
6. Targeting the cell cycle in the pursuit of novel chemotherapies against parasitic protozoa.
Grant KM
Curr Pharm Des; 2008; 14(9):917-24. PubMed ID: 18473840
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
[TBL] [Abstract][Full Text] [Related]
8. Polo and Aurora kinases: lessons derived from chemical biology.
Taylor S; Peters JM
Curr Opin Cell Biol; 2008 Feb; 20(1):77-84. PubMed ID: 18249108
[TBL] [Abstract][Full Text] [Related]
9. Anticancer drug targets: cell cycle and checkpoint control.
Shapiro GI; Harper JW
J Clin Invest; 1999 Dec; 104(12):1645-53. PubMed ID: 10606615
[No Abstract] [Full Text] [Related]
10. Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others.
Warner SL; Gray PJ; Von Hoff DD
Semin Oncol; 2006 Aug; 33(4):436-48. PubMed ID: 16890798
[TBL] [Abstract][Full Text] [Related]
11. Targeting polo-like kinase: learning too little too late?
Olmos D; Swanton C; de Bono J
J Clin Oncol; 2008 Dec; 26(34):5497-9. PubMed ID: 18955441
[No Abstract] [Full Text] [Related]
12. PLK1 as an oncology target: current status and future potential.
McInnes C; Wyatt MD
Drug Discov Today; 2011 Jul; 16(13-14):619-25. PubMed ID: 21601650
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of novel anti-cancer agents targeting aurora kinases.
Mahadevan D; Bearss DJ; Vankayalapati H
Curr Med Chem Anticancer Agents; 2003 Jan; 3(1):25-34. PubMed ID: 12678912
[TBL] [Abstract][Full Text] [Related]
14. Tangeretin induces cell-cycle G1 arrest through inhibiting cyclin-dependent kinases 2 and 4 activities as well as elevating Cdk inhibitors p21 and p27 in human colorectal carcinoma cells.
Pan MH; Chen WJ; Lin-Shiau SY; Ho CT; Lin JK
Carcinogenesis; 2002 Oct; 23(10):1677-84. PubMed ID: 12376477
[TBL] [Abstract][Full Text] [Related]
15. PLK1 inhibitors: setting the mitotic death trap.
Plyte S; Musacchio A
Curr Biol; 2007 Apr; 17(8):R280-3. PubMed ID: 17437704
[TBL] [Abstract][Full Text] [Related]
16. EORTC-NCI-AACR--20th symposium molecular targets and cancer therapeutics: mechanisms of targeting for cancer treatment.
Fakorede A
IDrugs; 2008 Dec; 11(12):857-8. PubMed ID: 19051142
[No Abstract] [Full Text] [Related]
17. Co-inhibition of polo-like kinase 1 and Aurora kinases promotes mitotic catastrophe.
Li J; Hong MJ; Chow JP; Man WY; Mak JP; Ma HT; Poon RY
Oncotarget; 2015 Apr; 6(11):9327-40. PubMed ID: 25871386
[TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase and its inhibitors: Ready for the match to start?
Palmisiano ND; Kasner MT
Am J Hematol; 2015 Nov; 90(11):1071-6. PubMed ID: 26294255
[TBL] [Abstract][Full Text] [Related]
19. 2-Aminoquinazoline inhibitors of cyclin-dependent kinases.
Bathini Y; Singh I; Harvey PJ; Keller PR; Singh R; Micetich RG; Fry DW; Dobrusin EM; Toogood PL
Bioorg Med Chem Lett; 2005 Sep; 15(17):3881-5. PubMed ID: 15993068
[TBL] [Abstract][Full Text] [Related]
20. Targeting the cell cycle in breast cancer: towards the next phase.
Thu KL; Soria-Bretones I; Mak TW; Cescon DW
Cell Cycle; 2018; 17(15):1871-1885. PubMed ID: 30078354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
